Sanofi wins EU nod for Dupixent to include new skin condition

Nov. 11, 2022 7:00 AM ETRegeneron Pharmaceuticals, Inc. (REGN), SNYSNYNF, GCVRZBy: Dulan Lokuwithana, SA News Editor

Exterior view of the Sanofi headquarters building

HJBC

  • An expert panel of the European Medicines Agency (EMA) has recommended issuing marketing authorization for Sanofi (NASDAQ:SNY) (OTCPK:SNYNF) to include the skin disorder prurigo nodularis as a use of injectable prescription medicine Dupixent.
  • Prurigo nodularis (PN) is a chronic inflammatory

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.